Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel

NCT01578564 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
23
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Soricimed Biopharma Inc